Company / R&D Expense
Altimmune, Inc. R&D Expense History
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$66.4M
FY2025
5-year range
$49.8M / $74.5M
FY2021-FY2025
Trend
+1.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense returned to growth in FY2025 after 2 years of decline, reaching $66M.
Based on SEC 10-K filings.
$66M in FY2025 with a 5-year CAGR of +30.2%.
Declined from $71M to $66M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -3.8%
- 5-Year CAGR
- +30.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +30.2%, indicating consistent growth.
- In FY2025, r&d expense increased 1.0% year-over-year.
- Peak r&d expense was recorded in FY2022.
- Lowest r&d expense in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -0.62 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $66.4M | +1.0% |
| FY2024 | $65.8M | -6.7% |
| FY2023 | $70.5M | -5.4% |
| FY2022 | $74.5M | +49.8% |
| FY2021 | $49.8M | +180.2% |
| FY2020 | $17.8M | -3.8% |
| FY2019 | $18.5M | +0.3% |
| FY2018 | $18.4M | +154.9% |
| FY2017 | $7.2M | -65.4% |
| FY2011 | $20.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026